PCM
ANIK icon

Prelude Capital Management’s Anika Therapeutics ANIK Stock Holding History

Prelude Capital Management’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-25,700
Closed -$1.49M – 1342
2017
Q3 		$1.49M Buy
25,700
+12,400
+93% +$648K 0.13% 158
2017
Q2 		$656K Sell
13,300
-1,700
-11% -$78.3K 0.06% 282
2017
Q1 		$652K Buy
+15,000
New +$716K 0.06% 305

Other funds holding ANIK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Prelude Capital Management's ANIK Position: Q2 2020 in Review

Prelude Capital Management sold out of Anika Therapeutics (ANIK) in Q2 2020, closing a stake of 1,490 shares — an estimated $43K sold.

Prelude Capital Management first reported a position in ANIK in Q1 2014 and held it in 8 quarters. The position peaked at $198K in Q4 2019. 158 funds tracked by Wall St. Rank hold ANIK as of Q2 2020.

  • Prelude Capital Management reported no remaining Anika Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Prelude Capital Management sold 1,490 Anika Therapeutics shares in Q2 2020, an estimated $43K.
  • Prelude Capital Management first reported a position in Anika Therapeutics in Q1 2014 and held it in 8 quarters.
  • Prelude Capital Management's Anika Therapeutics position peaked at $198K in Q4 2019.
  • 158 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2020.

Based on Prelude Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.